Graves' ophthalmopathy 1998;Endokrine orbitopathie 1998

Medizinische Klinik

Volumn 93, Issue 6, 1998, Pages 365-373

  Förster, Gregor ^b   Kahaly, George ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b Endokrinol Stoffwechselerkrankungen ^*

Author keywords

Diagnosis; Graves' ophthalmopathy; Pathogenesis; Therapy; Thyroid associated ophthalmopathy

Indexed keywords

CYCLOSPORIN A; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; AUTOIMMUNE DISEASE; CLINICAL TRIAL; ENDOCRINE OPHTHALMOPATHY; GRAVES DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PATHOGENESIS;

EID: 0032525863     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03044681     Document Type: Article

References (76)

1. Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy. N Engl J Med 1993;329:1468-75.
2. Bailey CC, Kabala J, Laitt R, et al. Magnetic resonance imaging in thyroid eye disease. Eye 1996,10.617-9
3. Balazs C, Kiss E, Vamos A, Molnar I, Fand NR Beneficial effect of pentoxifylline on thyroid associated ophthalmopathy: a pilot study. J Clin Endocrinol Metab 1997,82 1999-2002.
4. Bartalena L, Marcocci C, Pinchera A Cytokine antagonists new ideas for the management of Graves' ophthalmopathy J Clin Endocrinol Metab 1996;81:446-8
5. Bartley GB, Fatourechi V, Kadrmas EF, et al The treatment of Graves' ophthalmopathy in a incidence cohort Am J Ophthalmol 1996;121:200-6
6. Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996;121:284-90.
7. Bartley GB, Fatourechi V, Kadrmas EF, et al Chronology of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996,121 426-34.
8. Bohuslavizki KH, Oberwohrmann S, Brenner W, et al. 111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy Nucl Med Commun 1995;16 912-6.
9. Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993,14:747-93.
10. Burch HB, Sellitti D, Barnes SG, Nagy EV, Bahn RS, Burman KD Thyrotropin receptor antisera for the detection of immunoreactive protein species in retroocular fibroblasts obtained from patients with Graves' ophthalmopathy J Clin Endocnnol Metab 1994;78 1384-91.
11. Classification of eye changes of Graves' disease Thyroid 1992;2:235-6
12. Crisp MS, Lane C, Halliwell M, Wynford-Thomas D, Ludgate M Thyrotropin receptor transcripts in human adipose tissue J Clin Endocrinol Metab 1997;82:2003-5.
13. De Bellis A, Bizzarro A, Gattom A, et al. Behaviour of soluble intercelluler adhesion molecule-1 and endothelialleukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic ademoma J Clin Endocrinol Metab 1995,80:2118-21
14. De Carli M, D'Elios MM, Mariotti S, et al. Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy. J Clin Endocrinol Metab 1993;77.1120-4.
15. Durak I, Durak H, Ergin M, Yurekli Y, Kaynak S. Somatostatin receptors in the orbits. Clin Nucl Med 1995;20:237-42.
16. Esser J, Sauerwein W, Olbricht T. Corticoid- und Strahlentherapie bei endokriner Orbitopathie. Nuklearmedizin 1995;18:163-77.
17. Feliciello A, Porcellini A, Ciullo I, Bonavolontà G, Avvedimento E, Fenzi G. Expression of thyrotropin-receptor mRN A in healthy and Graves' disease retro-orbital tissue. Lancet 1993;342:337-8.
18. Forster G, Kahaly G. Rauchen und endokrine Orbitopathie Dtsch Med Wochenschr 1997;122 1060-1
19. Förster G, Otto E, Hansen C, Kahaly G. Analysis of orbital T cells recognizing retrobulbar antigens in Graves' ophthalmopathy. Clin Exp Immunol 1998;133 (im Druck).
20. Grubeck-Loeberistein B, Tneb K, Sztanky A, Holter W, Anderl H, Wick G. Retrobulbar T cells from patients with Graves' ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts. J Clin Invest 1994,93:2738-43.
21. Hansen C, Fraiture B, Rouhi R, Otto E, Förster G, Kahaly G. HPLC glycosaminoglycan analysis in patients with Graves' disease. Clin Sci 1997;92:511-7
22. Heufelder AE, Dutton CM, Sarkar G, Donovan KA, Bahn RS. Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves' ophthalmopathy and pretibial dermopathy. Thyroid 1993;3:297-300.
23. Heufelder AE, Bahn RS. Soluble intercellular adhesion molecule-1 (sICAM-1) in sera of patients with Graves' ophthalmopathy and thyroid diseases. Clin Exp Immunol 1993;92:296-302.
24. Heufelder AE, Bahn RS. Modulation of Graves' orbital fibroblast proliferation by cytokines and glucocorticoid receptor agonists. Invest Ophthalmol Vis Sci 1994;35:120-7.
25. Heufelder AE, Hertench S, Ernst G, Bahn RS, Scriba PC. Analysis of retroorbital T cell antigen receptor variable region gene usage in patients with Graves' ophthalmopathy. Eur J Endocrinol 1995,132 266-77.
26. Heufelder AE, Scriba PC. Characterization of adhesion receptors on cultured microvasculac endothelial cells derived from the retroorbital connective tissue of patients with Graves' ophthalmopathy. Eur J Endocrinol 1996,134,51-60.
27. Heufelder AE, Wenzel BE, Scriba PC. Antigen receptor variable region repertoires expressed by T cells infiltrating thyroid, retroorbital, and pretibial tissue in Graves' disease. J Clin Endocnnol Metab 1996,81 3733-9.
28. Hiromatsu Y, Tanaka K, Sato M, et al Intravenous methylprednisolone pulse therapy for Graves' ophthalmopathy. Endocr J 1993;40:63-72.
29. Hiromatsu Y, Sato M, Inoue Y, et al Localization and clinical significance of thyrotropin receptor mRNA expression in orbital fat and eye muscle tissue from patients with thyroid associated ophthalmopathy. Thyroid 1996;6 :553-62.
30. Hosojima H, Uchida K Availability of an anti platelet aggregation inhibitor, ticlopidine, in the treatment of Graves' ophthalmopathy. J Drug Dev Clin Pract 1996;8:129-33.
31. Kahaly G, Böckmann H, Beyer J, Bischoff S. Longterm observation of endocrine ophthalmopathy and retrospective appraisal of therapeutic measures J Endocrinol Invest 1990,13:287-92.
32. Kahaly G, Stover C, Otto E, Beyer J, Schuler M. Glycosaminoglycans in thyroid-associated ophthalmopathy. Autoimmunity 1992;13:81-8.
33. Kahaly G, Harisen C, Felke B, Dienes HP. Immunohistochemical staining of retrobulbar adipose tissue in Graves' ophthalmopathy. Clin Immunol Immunopathol 1994;73:53-62.
34. Kahaly G, Hansen C, Beyer J, Winand R. Plasma glycosaminoglycans in endocrine ophthalmopathy. J Endocrinol Invest 1994,17:45-50
35. Kahaly G, Diaz M, Hahn K, Beyer J, Bockisch A. Indium111-pentetreotide scinagraphy in Graves' ophthalmopathy. J Nucl Med 1995;36.550-4.
36. Kahaly G, Diaz M, Just M, Beyer J, Lieb W. Role of octreoscan and correlation with MR imaging in Graves' ophthalmopathy. Thyroid 1995,5 107-11
37. Kahaly G, Pitz S, Muller-Forell W, Hommel G. Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy. Clin Exp Immunol 1996,106:197-202
38. Kahaly G, Rösler HP, Köhler B, et al. Randomised trial comparing three irradiation protocols for endocrine orbitopathy (EO) Exp Clin Endocrinol Diab 1997,(Suppl) 1,31.
39. Kahaly G, Förster G, Pitz S, Rösler H-P, Mann W. Aktuelle interdisziplinare Diagnostik und Therapie der endokrinen Orbitopathie. Dtsch Med Wochenschr 1997;122;27-32.
40. Kalmann R, Mounts MP, van der Pol JP, Koomeef L Coronal approach for rehabilitative orbital decompression in Graves' ophthalmoparhy. Br J Ophthalmol 1997;81:41-5
41. Krassas GE, Dumas A, Pontikides N, Kaltsas T. Sornatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease Clin Endocrinol (Oxf) 1995,42:571-80.
42. Krassas GE, Kaltsas T, Dumas A, Pontikides N, Tolls G. Lanreotide in the treatment of patients with thyroid eye disease. Eur J Endocrinol 1997;136;416-22.
43. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe]- and [123I-Tyr3]-octreotide. the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20.716-31.
44. Kung AW, Michon J, Tai KS, Chan FL The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy. Thyroid 1996;6:381-4.
45. Major BJ, Cures A, Frauman AG. The full length and splice variant thyrotropin receptor is expressed exclusively in skeletal muscle of extraocular origin: a link to the pathogenesis of Graves' ophthalmopathy. Biochem Biophys Res Commun 1997;230 493-6.
46. Mann W, Kahaly G, Lieb W, Amedee R. Orbital decompression for endocrine ophthalmopathy: the endonasal approach. Am J Rhinol 1994;8:123-7.
47. McLachlan SM, Prummel MF, Rapoport B. Cell-mediated or humoral immunity in Graves' ophthalmopathy? Profiles of T-cell cytokines amplified by polymerase chain reaction from orbital tissue. J Clin Endocrinol Metab 1994;78:1070-4
48. McMab AA. Orbital decompression for thyroid orbitopathy. Aust NZJ Ophthalmol 1997;25:55-61
49. Metcalfe RA, Weetman AP. Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy. Clin Endocrinol (Oxf) 1994;40 67-72.
50. Molnar I, Balazs C. High circulating IL-6 levels in Graves' ophthalmopathy. Autoimmunity 1997;25:91-6.
51. Mounts MP, Koorneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy; a novel approach Br J Ophthalmol 1989,73:639-44.
52. Nakahara H, Noguchi S, Murakami N, et al. Graves' ophthalmopathy: MR evaluation of 10-Gy versus 24-Gy irradiation combined with systemic corticosteroids, Radiology 1995;196:857-62.
53. Otto AJ, Koorneef L, Mourits MP, Deen van Leewen L. Recrobulbar pressures measured during surgical decompression of the orbit Br J Ophthalmol 1996;80 1042-5.
54. Otto E, Ochs K, Hansen C, Wall J, Kahaly G Orbital tissue-derived T lymphocytes from patients with Graves' ophthalmopathy recognize autologous orbital antigens. J Clin Endocrinol Metab 1996;81 3045-50.
55. Otto E, Förster G, Kuhlemann K, Hansen C, Kahaly G. TSH receptor in endocrine autoimmunity. Clin Exp Rheumatol 1996,14:77-84.
56. Ozata M, Bolu E, Sengul A, et al. Soluble intercellular adhesion molecule-1 concentrations in patients with subacute thyroiditis and in patients with Graves' disease with or without ophthalmopathy. Endocr J 1996, 43 517-25.
57. Ozata M, Bolu E, Sengul A, et al. Effects of octreotide treatment on Graves' ophthalmopathy and circulating sICAM-1 levels. Thyroid 1996;6:283-8.
58. Pappa A, Calder V, Fells P, Lightman S. Adhesion molecule expression in vivo on extraocular muscles (EOM) in thyroid associated ophthalmopathy (TAO). Clin Exp Immunol 1997,108.309-13.
59. Paschke R, Vassarr G, Ludgate M Current evidence for and against the TSH receptor being the common antigen in Graves' disease and thyroid associated ophthalmopathy Clin Endocnnol 1995,42:565-9.
60. Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy impact of smoking severity and current vs lifetime cigarette consumption Clin Endocrinol (Oxf) 1996,45 477-81
61. Prummel MF, Mourits MP, Berghout A, et al. Prednisone and Cyclosporine in the treatment of severe Graves' ophthalmopathy N Engl J Med 1989;321:215-22
62. Prummel MF, Mounts MP, Blank L, Berghout A, Koornneef L, Wiersinga WM. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 1993;342 949-54.
63. Prummel MF, Wiersinga WM. Medical management of Graves' ophthalmopathy Thyroid 1995,5:231-4.
64. Saber E, McDonnell J, Zimmermann KM, Yugar JE, Feldon SE. Extraocular muscle changes in experimental orbital venous stasis: some similarities to Graves' orbitopathy. Graefes Arch Clin Exp Ophthalmol 1996;234: 331-6.
65. Salvi M, Spaggian E, Neri F, et al. The study of visual evoked potentials in patients with thyroid-associated ophthalmopathy identifies asymptomatic optic nerve involvement. J Clin Endocnnol Metab 1997;82:1027-30.
66. Seppel T, Schlaghecke R, Becker A, Engelbrecht V, Feidkamp J, Komely E. High-dose intravenous therapy with 7S immunoglobulins in autoimmune endocrine ophthalmopathy. Clin Exp Reumatol 1996;14:109-14.
67. Sorsky A, Pardasani D, Gagnon A, Smith TJ. Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. J Clin Endocrinol Metab 1996;81: 3428-31.
68. Stark B, Olivan N. Treatment of exophthalmus by orbital fat removal Clin Plast Surg 1993;20:285-9.
69. Stover C, Otto E, Beyer J, Kahaly G. Cellular immunity and retrobulbar fibroblasts in Graves' ophthalmopathy. Thyroid 1994;4:161-5.
70. Tagami T, Tanaka K, Sugawa H, et al. High dose intravenous steroid pulse therapy in thyroid associated ophthalmopathy. Endocr J 1996;43:689-99.
71. Tallstedt L, Lundell G. Radioiodine treatment, ablation, and ophthalmopathy: a balanced perspective. Thyroid 1997;7:241-5.
72. Tan GH, Dutton CM, Bahn RS. Interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptor inhibit IL-1-induced glycosaminoglycan production in cultured human orbital fibroblasts from patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 1996;81:449-52.
73. Wall JR, Kennerdell JS. Progress in thyroid-associated ophthalmopathy. Autoimmunity 1995;22:191-5.
74. Wall JR, Hayes M, Scalise D, et al. Native gel electrophoresis and isoelectric focusing of a 64-kilodalton eye muscle protein shows that it is an important target for serum antibodies in patients with thyroid-associated ophthalmopathy and not expressed in other skeletal muscle. J Clin Endocrinol Metab 1995;80 1226-32.
75. Weetman AP The role of T lymphocytes in thyroid-associated ophthalmopathy Autoimmunity 1992;13: 69-73.
76. Zhang ZG, JR Wall, Bernard NF. Tissue distribution and quantitation of a gene expressing a 64-kDa antigen associated with thyroid-associated ophthalmopathy. Clin Immunol Immunopathol 1996;80:236-44.